Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06868264 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 5, 2025 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 105 of 105 sites
    v12
  2. Study sites: 103 to 105v11
  3. Study sites: 100 to 103v10
  4. Study sites: 93 to 100v9
  5. Study sites: 86 to 93v8
Show 6 earlier versionsHide 6 earlier versions
  1. Study sites: 73 to 86v7
  2. Study sites: 54 to 73v6
  3. Study sites: 40 to 54v5
  4. Enrollment target: 800 to 880
    • Study sites: 19 to 40
    • Start date changed from estimate of Apr 2025 to Apr 7, 2025
    • Eligibility criteria shortened, about 2 words
    v4
  5. Study sites: 11 to 19v3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 11
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to compare the efficacy and safety of BEM/RZR to SOF/VEL in adults with chronic HCV.
Trial Details
NCT Number NCT06868264
Lead Sponsor Atea Pharmaceuticals, Inc.
Conditions
(from sponsor)		 HEPATITIS C VIRUS CHRONIC INFECTION
Enrollment 880 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov